Form 4 for CHRS Coherus Oncology, Inc.
Accepted 2024-12-17 00:00:00 ET · period of report 2024-12-13 · accession 0001610717-24-000542 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-12-17 | 2024-12-13 | CHRS | Reider Paul | Chief Commercial Off | F - Tax | $1.61 | -2,073 | 89.2K | -2% | -$3,338 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-12-13 | F | D | 2,073 | $1.61 | 89,204 | D | — | — | (F1) Represents shares automatically withheld by the Issuer to pay related tax liability in connection with the vesting of restricted stock units in accordance with Rule 16b-3. No shares were sold by the Reporting Person in connection with the foregoing transaction. (F2) Includes 5,000 shares acquired on November 15, 2024 and 5,000 shares acquired on May 15, 2024, each pursuant to the Coherus BioSciences, Inc. Employee Stock Purchase Plan. |